A Phase 4 interventional study of HAIC + Tirelizumab +lenvatinib +liver resection and liver resection in HCC, sponsored by Chen Xiaoping. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Chen Xiaoping · Phase 4, Interventional, and Treatment
Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). The intermediate stage (BCLC-B) HCC is highly heterogeneous, and there is no consensus on the treatment of this stage of the tumor in Western and Eastern countries. New tools are urgently needed to guide the choice of treatment options for patients with this stage of the tumor in order to reduce the risk of postoperative recurrence and the overall survival rate.
Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Intermediate stage (BCLC-B) HCC is heterogeneous, and there is no uniform consensus on the treatment of this stage of the tumor in Western and Chinese countries, while the European guidelines recommend liver transplantation, transarterial chemoembolization (TACE), and systemic medication as the first line of treatment. In Eastern countries, such as China, BCLC-B is further categorized into stages IIa and IIb, and surgical resection is recommended as the first-line treatment option for stage IIa, while surgical resection can also be considered for stage IIb. Retrospective studies have found that surgical resection has an overall better prognosis than non-surgical treatment. However, the rate of postoperative recurrence is higher than that of early HCC. To address this issue, new tools are urgently needed to guide the selection of appropriate treatment regimens to reduce the risk of postoperative recurrence and overall survival.
Our multidisciplinary team used deep learning technology to construct an artificial intelligence prediction model of neoadjuvant therapy benefit based on pre-treatment genetic testing data, digital pathology slides and imaging data (enhanced MRI) of 536 intermediate-stage HCC patients treated with HAIC in combination with lenvatinib and PD-1 monoclonal antibody in six centers, and external center data validated the model's good ability to identify the beneficiary population of the combination regimen ( AUC 0.89, Accuracy 0.86). The aim of this study is to study the effectiveness and safety of New-adj-Net in improving the progression of intermediate-stage HCC patients during neoadjuvant therapy and postoperative recurrence by observing the benefit of the combined neoadjuvant regimen in patients who are potentially benefited from neoadjuvant therapy and direct surgery from the perspective of precision therapy.
Chen Xiaoping is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in the neoadjuvant therapy group received neoadjuvant therapy before undergoing liver resection.
Drug: HAIC + Tirelizumab +lenvatinib +liver resection
Patients in the control group undergoing liver resection directly.
Procedure: liver resection
Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
Also known as: Non
Direct liver resection or laparoscopic liver resection depending on tumor status.
Disease-free survival
DFS defined as the time after surgical resection until tumor recurrence or death
Time frame: From date of include in this research until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.
Safety Assessment
Any adverse event during treatment that is incompatible with the therapeutic purpose of the medication.
Time frame: 2 months
No study locations are listed for this record.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chen Xiaoping